Lupin

General

23 January, 2017

How bad could the Trump presidency really be for India?

Ever since Donald Trump won the US presidential election held on 8 November last year, speculation has been rife about ......

General

08 November, 2016

US election: What a Clinton or a Trump victory may mean for India Inc

So, the D-day is here and voters in the US will cast their ballot to elect their next president on ......

Healthcare

23 April, 2014

Lupin inks Japanese biosimilars joint venture with Yoshindo

Mumbai-based pharma major Lupin Limited has entered into a strategic joint venture agreement with Toyama-based pharmaceuticals company, Yoshindo Inc. (Yoshindo) ......

Healthcare

22 April, 2014

Lupin ropes in Theresa Stevens to head global M&As

Mumbai-based pharma major Lupin Ltd has appointed Theresa Stevens as chief corporate development officer for its global operations and will ......

Healthcare

27 March, 2014

Lupin acquires Mexico-based ophthalmic drugs maker Laboratorios Grin

Mumbai-based pharmaceutical firm Lupin Ltd has forayed into Mexican market with the acquisition of 100 per cent equity stake in ......

Healthcare

03 February, 2014

Lupin acquires Dutch complex injectables firm Nanomi

Mumbai-based pharma major Lupin Ltd has acquired Dutch firm Nanomi B.V. for an undisclosed amount, as per a stock market ......

Healthcare

30 October, 2013

Lupin clocks 40% growth in PAT on higher other income; sales up 18% in Q2

Mumbai-based pharma major Lupin Ltd has posted a 40 per cent growth in its profit after tax (PAT) for the ......

Healthcare

18 September, 2013

Lupin gets US FDA nod to manufacture generic insomnia drug

Mumbai-based pharma major Lupin Ltd has received the final approval from US Food and Drug Administration (FDA) to manufacture and ......

General

05 April, 2013

The ‘greatness' conundrum

Indian companies find it very hard to generate shareholder returns – over the last 20 years, 80 per cent of ......

Others

18 March, 2013

The ‘greatness' conundrum

Indian companies find it very hard to generate shareholder returns – over the last 20 years, 80 per cent of ......